on the market now, how can doctors or governments decide which one is the most cost-effective?
Modeling the cost of a disease is never easy, but somehow it seems particularly difficult for MS since the disease has so many parameters to be analyzed. A recent systematic review on this subject 1 showed that different authors use different models for assessing cost-effectiveness. In fact, the differences are so wide that some models 2 consider two years and others 3 ten years of MS treatment for their cost estimates. Furthermore, all countries in which this matter has been studied have produced different results regarding cost-effectiveness because the drugs have different prices in different countries, as do the examinations, other consultations and treatments, and the disability aids that come with the disease. Lessons from pharmacoeconomics cannot be transplanted from one country to another; each country will have to perform its own studies in order to understand which strategy is best for treating MS. Simply introducing a "cheaper" medication does not mean better cost-effectiveness in a chronic and complex disease like MS. The benefits (or lack) of cheaper generic drugs or biosimilars may not be understood until ten years have passed, at which time it is too late for the patient and for the healthcare system. The subject raised by Romano et al. 4 is of paramount importance in our continent. We struggle with a variety of problems in Latin American healthcare systems. Those with the power to make decisions regarding MS treatments need to be aware of the cost-effectiveness of present drugs, new drugs, biosimilars, complex molecules, etc. Without the aid of pharmacoeconomic analyses, we may never achieve the best cost-effective treatment for any disease. The examples put forth by researchers, who have already started studying and publishing on this subject, have to be followed by the rest of us.
